Trial Profile
A Pharmacokinetic Study in Chinese Healthy Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of Ensartinib Capsules
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Ensartinib (Primary)
- Indications CNS cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Betta Pharmaceuticals Co Ltd
- 01 Mar 2022 Results evaluating the effects of food on the pharmacokinetics of ensartinib after a single dose (225 mg) in healthy Chinese subjects, published in the Clinical and Experimental Pharmacology and Physiology
- 22 Jul 2019 Status changed from recruiting to completed.
- 17 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.